Results 11 to 20 of about 12,098 (189)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations [PDF]

JTO Clinical and Research Reports, 2021
Introduction: In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations. Methods: ROS1 immunohistochemistry (IHC) was performed using the ROS1 (SP384) class I assay per
Richard S.P. Huang, MD, Amanda Gottberg-Williams, BS, Panhia Vang, BS, Shoua Yang, HSD, Nicholas Britt, BS, Jaspreet Kaur, MS, James Haberberger, BS, Natalie Danziger, BS, Clarence Owens, BS, Sara E. Beckloff, PhD, Jeffrey S. Ross, MD, Shakti H. Ramkissoon, MD, PhD   +11 more
doaj   +3 more sources

Unique fusion is associated with marked response to crizotinib in lung adenocarcinoma [PDF]

SAGE Open Medical Case Reports, 2022
Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors.
Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo, Carlos Diego Holanda Lopes, Rodrigo Saddi, João Victor Machado Alessi, Mariana Petaccia de Macedo, Ellen Caroline Toledo do Nascimento, Leonardo de Abreu Testagrossa, Artur Katz   +9 more
doaj   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients [PDF]

Molecular Oncology
Clinical outcomes in ROS1‐fusion positive (ROS1+) non‐small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 ...
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van denBerg, Lyndsay Drayer, Anthonie van derWekken   +8 more
doaj   +2 more sources

Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT) [PDF]

Cancer Reports
Background Inflammatory myofibroblastic tumor (IMTs) are rare mesenchymal neoplasms with slow growth. Resection is considered as therapeutic standard, with chemotherapy being insufficiently effective in advanced disease. ALK translocations are present in
Sebastian Sommer, Maximilian Schmutz, Tina Schaller, Patrick Mayr, Sebastian Dintner, Bruno Märkl, Ralf Huss, M. Monika Golas, Michaela Kuhlen, Frank Jordan, Rainer Claus, Bernhard Heinrich   +11 more
doaj   +2 more sources

: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing

Clinical Pathology
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners ...
Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh   +8 more
doaj   +3 more sources

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. [PDF]

NPJ Precis Oncol
AbstractPurposeDespite the robust efficacy of ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-positive non-small cell lung cancer, TKI resistance continues to hamper durability of the therapeutic response. The resistance liabilities of next-generation ROS1 TKI are sparsely characterized.DesignWe compared the activity of type I TKIs (crizotinib ...
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA.   +9 more
europepmc   +6 more sources

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach:A multi-institutional research study [PDF]

, 2018
Contains fulltext : 195300.pdf (publisher's version ) (Open ...
A Marchetti, A Uguen, A Vaishnavi, AK Virmani, Aldo Scarpa, Alexander Boag, Andrea Mafficini, Anna Maria Rachiglio, Anne Reiman, Astrid Hirschmann, Bastiaan Tops, Cancer Genome Atlas Research N, Cecily P. Vaughn, D Matsubara, Delphine Le Corre, E Ardini, F Li, Federica Zito Marino, Harriet E. Feilotter, Henriette M. Kurth, Hélène Blons, Ian A. Cree, JF Gainor, José Carlos Machado, José Luis Costa, JP Koivunen, K Rikova, K Takeuchi, Kazuko Sakai, Kazuto Nishio, KD Davies, Kelli Bramlett, KF To, L Ding, L Tembuyser, LM Sholl, M Soda, Marjolijn J. L. Ligtenberg, ME Lira, Michel Bihl, ML Wallander, N Pfarr, Nicola Normanno, Orla Sheils, Pierre Laurent-Puig, RM Phelps, Rosella Petraroli, Roy R. L. Bastien, S Scarpino, SM Ali, Susan Crocker, T Kohno, Varun Bagai, X Gao, Y Pan, Z Dai   +55 more
core   +16 more sources

Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms. [PDF]

Mod Pathol, 2021
The presence of a characteristic chimeric fusion as the initiating genomic event is one defining feature of Spitz neoplasms. Characterization of specific subtypes of Spitz neoplasms allows for better recognition facilitating diagnosis. Data on clinical outcomes of the specific tumor types may help in predicting behavior.
Gerami P, Kim D, Compres EV, Zhang B, Khan AU, Sunshine JC, Quan VL, Busam K.   +7 more
europepmc   +4 more sources

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China

Frontiers in Cell and Developmental Biology, 2022
Objective: This study aimed to identify ROS1 fusion partners in Chinese patients with solid tumors.Methods: Next-generation sequencing (NGS) analysis was used to detect ROS1 rearrangement in 45,438 Chinese patients with solid tumors between 2015 and 2020,
Ning Li, Zhiqin Chen, Mei Huang, Ding Zhang, Mengna Hu, Feng Jiao, Ming Quan   +6 more
doaj   +1 more source

Advances and future directions in ROS1 fusion-positive lung cancer. [PDF]

Oncologist
Abstract ROS1 gene fusions are an established oncogenic driver comprising 1%-2% of non–small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small-molecule tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape of metastatic ROS1 fusion-positive (ROS1+) NSCLC and transformed ...
Boulanger MC, Schneider JL, Lin JJ.
europepmc   +3 more sources